Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shyam Tanguturi"'
Autor:
Caitlyn Kwan, BS, Yu-Hui Chen, MS, MPH, Joseph H. Killoran, PhD, Marco Ferrone, MD, Karen J. Marcus, MD, Shyam Tanguturi, MD, Tracy A. Balboni, MD, MPH, Alexander Spektor, MD, PhD, Mai Anh Huynh, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 9, Iss 4, Pp 101439- (2024)
Purpose: There are limited data regarding outcomes after stereotactic body radiation therapy (SBRT) for femur metastases, which was an exclusion criteria for the Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Ca
Externí odkaz:
https://doaj.org/article/72caac66615249369130ac87b35b0d9a
Autor:
Benjamin L Ebert, Naomi Galili, Pablo Tamayo, Jocelyn Bosco, Raymond Mak, Jennifer Pretz, Shyam Tanguturi, Christine Ladd-Acosta, Richard Stone, Todd R Golub, Azra Raza
Publikováno v:
PLoS Medicine, Vol 5, Iss 2, p e35 (2008)
Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell production and a predisposition to the development of leukemia. Patie
Externí odkaz:
https://doaj.org/article/d679c3f20229452882e62efd8e30fdae
Autor:
Nayan Lamba, Daniel N Cagney, Paul J Catalano, Hesham Elhalawani, Daphne A Haas-Kogan, Patrick Y Wen, Nikhil Wagle, Nancy U Lin, Ayal A Aizer, Shyam Tanguturi
Publikováno v:
Neuro-Oncology. 25:973-983
Background Leptomeningeal disease (LMD) is a relatively uncommon manifestation of advanced cancer. Patients with LMD carry a poor prognosis and often decline rapidly, complicating inclusion in clinical trials. Identification of LMD subsets of greater
Autor:
Zhaohui Han, Atchar Sudhyadhom, Shu‐Hui Hsu, Yue‐Houng Hu, Raymond H. Mak, Mai Anh Huynh, Ritchell R. van Dams, Shyam Tanguturi, Veena Venkatachalam, Joseph D. Mancias, Harvey J. Mamon, Neil E. Martin, Miranda B. Lam, Jonathan E. Leeman
Publikováno v:
Journal of Applied Clinical Medical Physics.
Autor:
Fabio Iwamoto, Shyam Tanguturi, Arati Desai, Lakshmi Nayak, Erik Uhlmann, Tony Wang, Robert Lustig, Lauren Hertan, Stephen Bagley, Julia Hayden, Corey Laforest-Roys, Alona Muzikansky, Christine McCluskey, Ugonma Chukwueke, J Ricardo McFaline-Figueroa, Eudocia Lee, Patrick Y Wen, David Reardon
Publikováno v:
Neuro-Oncology. 24:vii63-vii64
Re-irradiation is therapeutically considered for select rGBM patients and may induce immunogenic cell death to stimulate anti-tumor immune responses. Our phase 2 study of re-irradiation with pembrolizumab among rGBM patients evaluated the efficacy an
Autor:
Anurag Saraf, Cameron Hill, Gilbert Youssef, Sebastian Christ, Shyam Tanguturi, J Ricardo McFaline-Figueroa, Ugonma Chukwueke, Eudocia Lee, David A Reardon, Omar Arnaout, Wenya Linda Bi, Daphne Haas-Kogan, Keith Ligon, Brian Alexander, Patrick Y Wen, Rifaquat Rahman
Publikováno v:
Neuro-Oncology. 24:vii12-vii12
BACKGROUND Treatment-related toxicity is common in patients with glioblastoma (GBM) receiving chemotherapy and radiotherapy (RT). Temporalis muscle thickness (TMT) is a biomarker associated with sarcopenia and worse clinical outcomes in GBM, however
Autor:
Lakshmi Nayak, Shanna Dowling, Brian M. Alexander, David Meredith, Sandro Santagata, E. Antonio Chiocca, Omar Arnaout, Brittany Fisher-Longden, Daphne H. Haas-Kogan, Geffrey Fell, Jack Geduldig, Rifaquat Rahman, Daniel Cagney, Ayal Aizer, Howard Colman, Christine Lu-Emerson, Tracy T. Batchelor, Thomas Kaley, Jan Drappatz, Patrick Y. Wen, Andrew B. Lassman, Maria Lavallee, Mehdi Touat, Ingo K. Mellinghoff, David Schiff, Manmeet Ahluwalia, Rameen Beroukhim, Shyam Tanguturi, Lisa Doherty, Lorenzo Trippa, Jaroslaw T. Hepel, Wenya Linda Bi, David A. Reardon, Jennifer Bruno, Sarah Gaffey, Keith L. Ligon, Ugonma Chukwueke, Christine McCluskey, Heinrich Elinzano, Evanthia Galanis, Mary Welch, Isabel Arrillaga-Romany, Fiona Watkinson, Pierpaolo Peruzzi, J Ricardo McFaline-Figueroa, Eudocia Q. Lee, L. Burt Nabors
Publikováno v:
Neuro Oncol
BACKGROUND The cyclin D-CDK4/6-Rb pathway is activated in most glioblastomas. Abemaciclib is a potent CDK4/6 inhibitor with good brain penetration approved for ER/PR/HER2- breast cancer. In order to efficiently evaluate the potential impact of abemac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f98386b72dd15b115ee794c232f42336
https://europepmc.org/articles/PMC7650442/
https://europepmc.org/articles/PMC7650442/
Autor:
Isabel Arrillaga-Romany, Lorenzo Trippa, Geffrey Fell, Eudocia Quant Lee, Rifaquat Rahman, Mehdi Touat, Christine McCluskey, Jennifer Bruno, Sarah Gaffey, Jan Drappatz, Andrew Lassman, Evanthia Galanis, Manmeet Ahluwalia, Howard Colman, L Burt Nabors, Jaroslaw Hepel, Heinrich Elinzano, Thomas Kaley, Ingo K Mellinghoff, David Schiff, Ugonma Chukwueke, Rameen Beroukhim, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Tracy Batchelor, Christine Lu-Emerson, Wenya Linda Bi, Omar Arnaout, Pierpaolo Peruzzi, Daphne Haas-Kogan, Shyam Tanguturi, Daniel Cagney, Ayal Aizer, Mary Welch, Lisa Doherty, Maria Lavallee, Brittany Fisher-Longden, Shanna Dowling, Jack Geduldig, Fiona Watkinson, Sandro Santagata, David Meredith, E Antonio Chiocca, David Reardon, Keith Ligon, Brian Alexander, Patrick Wen
Publikováno v:
Neuro-Oncology. 23:vi59-vi59
BACKGROUND EGFR is amplified in over 50% of glioblastoma and 20-30% have EGFRvIII mutations. Neratinib is a potent inhibitor of EGFR/HER2 approved for metastatic HER2+ breast cancer. To efficiently evaluate the potential impact of neratinib on overal